| Martha Hosford Skapof, MD | |
|
4701 Ogletown Stanton Rd, Suite 2400, Newark, DE 19713-2055 | |
| (302) 731-7782 | |
| (302) 738-5917 |
| Full Name | Martha Hosford Skapof |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 40 Years |
| Location | 4701 Ogletown Stanton Rd, Newark, Delaware |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457301657 | NPI | - | NPPES |
| 0000049801 | Medicaid | DE | |
| 0011089490010 | Medicaid | PA | |
| 0161701001 | Medicaid | MD |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health | Elkton, MD | Home health agency |
| Union Hospital Of Cecil County | Elkton, MD | Hospital |
| Chester County Hospital | West chester, PA | Hospital |
| Christiana Hospital | Newark, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Christiana Care Health Services Inc | 9739097569 | 1248 |
| Christiana Care Health Services Inc | 9739097569 | 1248 |
News Archive
BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma" by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology.
A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause of maternal and infant death worldwide, a discovery that could lead to the development of new therapeutic treatments.
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.
Researchers in the United States say folic acid supplements may reduce the risk of stroke by more than 18 percent.
Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN MINI and INOGEN MINI ICDs, as well as the DYNAGEN X4 and INOGEN X4 CRT-Ds.
› Verified 9 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770568107 PECOS PAC ID: 9739097569 Enrollment ID: O20031201000477 |
News Archive
BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma" by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology.
A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause of maternal and infant death worldwide, a discovery that could lead to the development of new therapeutic treatments.
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.
Researchers in the United States say folic acid supplements may reduce the risk of stroke by more than 18 percent.
Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN MINI and INOGEN MINI ICDs, as well as the DYNAGEN X4 and INOGEN X4 CRT-Ds.
› Verified 9 days ago
| Entity Name | Regional Hematology And Oncology P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811947054 PECOS PAC ID: 0749175586 Enrollment ID: O20070521000381 |
News Archive
BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma" by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology.
A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause of maternal and infant death worldwide, a discovery that could lead to the development of new therapeutic treatments.
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.
Researchers in the United States say folic acid supplements may reduce the risk of stroke by more than 18 percent.
Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN MINI and INOGEN MINI ICDs, as well as the DYNAGEN X4 and INOGEN X4 CRT-Ds.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Martha Hosford Skapof, MD 4701 Ogletown Stanton Rd, Suite 2400, Newark, DE 19713-2055 Ph: (302) 731-7782 | Martha Hosford Skapof, MD 4701 Ogletown Stanton Rd, Suite 2400, Newark, DE 19713-2055 Ph: (302) 731-7782 |
News Archive
BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma" by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology.
A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause of maternal and infant death worldwide, a discovery that could lead to the development of new therapeutic treatments.
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.
Researchers in the United States say folic acid supplements may reduce the risk of stroke by more than 18 percent.
Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN MINI and INOGEN MINI ICDs, as well as the DYNAGEN X4 and INOGEN X4 CRT-Ds.
› Verified 9 days ago
Shruti Puri, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd Ste 5a43, Newark, DE 19718 Phone: 302-623-0188 Fax: 302-733-5640 | |
Zaid A Ammari, M.D. M.P.H. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-1000 Fax: 347-851-8707 | |
Dr. Suresh Trivedi, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 111 Continental Dr, Suite 406, Newark, DE 19713 Phone: 302-368-2630 Fax: 302-368-1271 | |
Dr. Bradley Bley, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1096 Old Churchmans Rd, Newark, DE 19713 Phone: 302-655-9494 Fax: 302-351-4898 | |
Dr. Avinash Chandra, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 86 Omega Dr, Omega Professional Center, Building B-86, Newark, DE 19713 Phone: 302-366-1929 Fax: 302-366-1006 | |
Dr. Lucinda Li, DO Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4755 Ogletown Stanton Rd Ste 5a43, Newark, DE 19718 Phone: 302-623-0188 | |
Dr. James Robinson Mcninch Iv, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-1148 |